B cell depletion to prevent autoimmunity
B 细胞耗竭以预防自身免疫
基本信息
- 批准号:10439680
- 负责人:
- 金额:$ 39.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-15 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAncillary StudyAntigensAutoimmuneAutoimmune DiseasesAutoimmunityB cell differentiationB-Lymphocyte SubsetsB-LymphocytesCell physiologyCellsClinicalClinical TrialsClone CellsCombined Modality TherapyCytometryDataDevelopmentEnrollmentEpigenetic ProcessFrequenciesGene Expression ProfileGenetic TranscriptionGenomicsHelper-Inducer T-LymphocyteHumanImmuneImmunityImmunologicsIn VitroIncidenceInterventionLupusMalignant NeoplasmsMediatingMolecularMyeloid CellsParentsPathogenicityPathway interactionsPatient-Focused OutcomesPatientsPatternPhenotypePlasmablastPlayPropertyRandomized Clinical TrialsRecoveryResearch PersonnelRiskRoleSeveritiesSystemic Lupus ErythematosusT memory cellT-LymphocyteTestingTissuesanti-CTLA4anti-PD-1anti-PD1 antibodiesautoreactive B cellautoreactivitybasedesignexhaustexperienceimmune checkpoint blockadeimmune-related adverse eventsin vivoinsightmelanomapreventprogramsrituximabsingle cell analysisstandard of caretositumomabtranscription factortranscriptomicstumortumor immunology
项目摘要
PROJECT SUMMARY
Immune related adverse events (IRAEs) remain a major obstacle to optimal application of combination
checkpoint blockade in human cancer. Deeper understanding of the mechanisms underlying these IRAEs, and
in particular underlying cellular and genomic pathways and antigenic targets is essential to develop optimal
strategies to prevent and treat these AEs. This application represents a collaborative effort between two
investigators with experience in cancer immunology (KD) and human autoimmunity (IS) to investigate the role of
B cells in IRAEs. It builds directly on our prior studies evaluating early immunologic changes in patients
undergoing immune checkpoint blockade, as well studies of altered B cell differentiation and function underlying
human autoimmune disorders. In these studies, we have observed that CCB therapy leads to a distinct pattern
of changes in B cells, particularly involving CD21lo B cell subset and plasmablasts. We have also identified
distinct epigenetic and transcriptional signatures of B cells in autoimmune disorders such as lupus. Our
hypothesis is that preexisting changes in autoreactive B cells will identify patients at risk for early IRAEs. We
further posit that CCB-induced expansion of pathogenic B cells is mediated by the engagement of epigenetic
and transcriptomic programs akin to those observed in naturally occurring autoimmunity. B cells have been
proposed to play both a pro- and anti-tumor role in cancer. In order to specifically isolate the effect of B cells in
IRAEs, we will evaluate changes in pathogenic B cells and plasmablasts in the context of a randomized clinical
trial to specifically deplete B cells in melanoma patients undergoing CCB. The specific aims of the project are:
Aim 1. To assess whether pre-existing transcriptional and epigenetic alterations in B cell subsets identify
patients at risk for CCB-induced irAEs and are normalized by Rituxan
Aim 2. To evaluate Rituxan-mediated depletion of pathogenic B cells and their contribution to irAEs
following CCB.
Aim 3. To evaluate whether depletion of B cells leads to alterations in circulating or tumor-infiltrating T
cells in patients undergoing CCB.
Together these studies will provide direct insights into the relative contribution of B cells in patients undergoing
CCB, both in terms of favorable as well as adverse impact on tumor-immune interactions and patient outcome.
Understanding these cellular interactions directly in humans is essential for developing rational approaches to
prevent IRAEs.
项目摘要
免疫相关不良事件(IRAE)仍然是最佳联合应用的主要障碍
检查点封锁在人类癌症中的作用更深入地了解这些IRAE的机制,
特别是潜在的细胞和基因组途径以及抗原靶点对于开发最佳的
预防和治疗这些AE的策略。这个应用程序代表了两个
具有癌症免疫学(KD)和人类自身免疫(IS)经验的研究人员研究了
IRAE中的B细胞。它直接建立在我们先前评估患者早期免疫学变化的研究基础上
进行免疫检查点阻断,以及改变B细胞分化和功能的研究,
人类自身免疫性疾病在这些研究中,我们观察到CCB治疗导致了一种独特的模式,
B细胞的变化,特别是涉及CD 21 lo B细胞亚群和浆母细胞。我们还确定
自身免疫性疾病如狼疮中B细胞的不同表观遗传和转录特征。我们
一个假设是,自身反应性B细胞的预先存在的变化将识别出处于早期IRAE风险中的患者。我们
进一步证实CCB诱导的致病性B细胞的扩增是由表观遗传的参与介导的,
和类似于在天然发生的自身免疫中观察到的那些的转录组程序。B细胞已经
被认为在癌症中同时发挥促肿瘤和抗肿瘤作用。为了特异性地分离B细胞在
IRAE,我们将在随机临床试验的背景下评估致病性B细胞和浆母细胞的变化。
在接受CCB的黑色素瘤患者中特异性耗竭B细胞的试验。该项目的具体目标是:
目标1.评估B细胞亚群中预先存在的转录和表观遗传学改变是否确定了
存在CCB诱导的irAE风险并通过Rituxan恢复正常的患者
目标二。评价利妥昔单抗介导的致病性B细胞耗竭及其对irAE的贡献
在CCB之后
目标3。评价B细胞耗竭是否导致循环或肿瘤浸润性T细胞的改变,
接受CCB的患者的细胞。
总之,这些研究将提供直接的见解,B细胞在患者中的相对贡献,
CCB对肿瘤免疫相互作用和患者结局的有利和不利影响。
直接了解人体内这些细胞间的相互作用对于开发合理的方法,
预防IRAE。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kavita Madhav Dhodapkar其他文献
Kavita Madhav Dhodapkar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kavita Madhav Dhodapkar', 18)}}的其他基金
Emory Clinical Oncology Career Development Award K12 Program
埃默里临床肿瘤学职业发展奖 K12 计划
- 批准号:
10188464 - 财政年份:2019
- 资助金额:
$ 39.71万 - 项目类别:
Emory Clinical Oncology Career Development Award K12 Program
埃默里临床肿瘤学职业发展奖 K12 计划
- 批准号:
10438571 - 财政年份:2019
- 资助金额:
$ 39.71万 - 项目类别:
B cells in autoimmunity following checkpoint blockade therapy
检查点阻断治疗后的自身免疫中的 B 细胞
- 批准号:
9893845 - 财政年份:2019
- 资助金额:
$ 39.71万 - 项目类别:
B cells in autoimmunity following checkpoint blockade therapy
检查点阻断治疗后的自身免疫中的 B 细胞
- 批准号:
10369680 - 财政年份:2019
- 资助金额:
$ 39.71万 - 项目类别:
B cells in autoimmunity following checkpoint blockade therapy
检查点阻断治疗后的自身免疫中的 B 细胞
- 批准号:
10578752 - 财政年份:2019
- 资助金额:
$ 39.71万 - 项目类别:
Emory Clinical Oncology Career Development Award K12 Program
埃默里临床肿瘤学职业发展奖 K12 计划
- 批准号:
10680377 - 财政年份:2019
- 资助金额:
$ 39.71万 - 项目类别:
相似海外基金
A Longitudinal Study of Periodontal Infections and Alzheimer's Disease: The WHICAP Ancillary Study of Oral Health
牙周感染和阿尔茨海默病的纵向研究:口腔健康的 WHICAP 辅助研究
- 批准号:
10381292 - 财政年份:2021
- 资助金额:
$ 39.71万 - 项目类别:
Coronary Artery Calcium in the PRagmatic EValuation of evENTs And Benefits of Lipid lowering in the Elderly: CAC PREVENTABLE Ancillary Study
冠状动脉钙对老年人降脂事件和益处的实用评估:CAC 可预防的辅助研究
- 批准号:
10674482 - 财政年份:2021
- 资助金额:
$ 39.71万 - 项目类别:
The PREVENTABLE Physical Performance Ancillary Study
可预防的身体表现辅助研究
- 批准号:
10366941 - 财政年份:2021
- 资助金额:
$ 39.71万 - 项目类别:
The PREVENTABLE Physical Performance Ancillary Study
可预防的身体表现辅助研究
- 批准号:
10495229 - 财政年份:2021
- 资助金额:
$ 39.71万 - 项目类别:
StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study
他汀类药物在脑出血患者中的使用 MRI (SATURN MRI) 辅助研究
- 批准号:
10179775 - 财政年份:2021
- 资助金额:
$ 39.71万 - 项目类别:
Mechanistic Ancillary Study to the Natural History Study of ADO2 to Determine Clinical Severity
ADO2 自然史研究的机制辅助研究以确定临床严重程度
- 批准号:
10375070 - 财政年份:2021
- 资助金额:
$ 39.71万 - 项目类别:
A Longitudinal Study of Periodontal Infections and Alzheimer's Disease: The WHICAP Ancillary Study of Oral Health
牙周感染和阿尔茨海默病的纵向研究:口腔健康的 WHICAP 辅助研究
- 批准号:
10631203 - 财政年份:2021
- 资助金额:
$ 39.71万 - 项目类别:
Coronary Artery Calcium in the PRagmatic EValuation of evENTs And Benefits of Lipid lowering in the Elderly: CAC PREVENTABLE Ancillary Study
冠状动脉钙对老年人降脂事件和益处的实用评估:CAC 可预防的辅助研究
- 批准号:
10296788 - 财政年份:2021
- 资助金额:
$ 39.71万 - 项目类别:
COCOA PAD II Trial: Microbiome Ancillary Study
COCOA PAD II 试验:微生物组辅助研究
- 批准号:
10610072 - 财政年份:2021
- 资助金额:
$ 39.71万 - 项目类别: